Lactoferricin

What is Lactoferricin?

Lactoferricin is the antimicrobial peptide core of lactoferrin, the iron-binding glycoprotein that is abundant in mammalian milk (especially colostrum), saliva, tears, seminal fluid, and the secondary granules of neutrophils. It was identified in 1992 by W. Bellamy, M. Takase, K. Yamauchi, H. Wakabayashi, K. Kawase and M. Tomita at the Nutritional Science Laboratory of Morinaga Milk Industry Co. Ltd. in Zama City, Kanagawa, Japan. The team subjected bovine lactoferrin to pepsin digestion and identified the bactericidal activity as residing in a 25-amino-acid peptide corresponding to residues 17-41 of the bovine lactoferrin N-terminal lobe — the 1992 Biochim Biophys Acta paper reported 'the existence of a previously unknown antimicrobial domain near the N-terminus of lactoferrin' and is titled 'Identification of the bactericidal domain of lactoferrin'; the name 'lactoferricin B' first appears in the group's own December 1992 J Appl Bacteriol spectrum paper. The frequently-quoted phrase 'Lactoferricin, a new antimicrobial peptide' is the title of a different 1994 J Appl Bacteriol paper by Jones and colleagues at the Bristol Royal Infirmary, not of Bellamy's discovery paper. The human homolog (Lfcin-H or hLF1-47) corresponds to residues 1-47 of human lactoferrin and is generated similarly by pepsin or in vivo gastric proteolysis. Both forms are cationic, amphipathic peptides with a high content of arginine, lysine, and tryptophan residues — the structural signature of pore-forming antimicrobial peptides — and both adopt amphipathic conformations stabilized by intramolecular disulfide bonds when in solution. The 1998 Hwang et al. NMR structure paper resolved the three-dimensional solution structure of Lfcin-B and confirmed the amphipathic architecture that mediates microbial-membrane disruption. Functionally, lactoferricin has broad-spectrum antimicrobial activity against Gram-positive bacteria, Gram-negative bacteria, fungi (including Candida albicans), enveloped viruses (notably herpes simplex virus), and parasites — an activity profile typical of the cationic antimicrobial peptide class. Beyond direct antimicrobial action, lactoferricin and its derivatives induce apoptosis in tumor cell lines through mitochondrial-pathway-dependent mechanisms (Mader 2005), have antiviral activity against herpes simplex virus and other enveloped viruses (Jenssen 2005), and exhibit anti-biofilm activity against Candida and bacterial multi-species biofilms. Drug development around lactoferricin has produced several derivative peptides — most prominently hLF1-11, an 11-residue fragment in clinical-stage development for fungal and bacterial infections — but no lactoferricin-based product has reached broad approval as of 2026.

What Lactoferricin Is Investigated For

Lactoferricin is an antimicrobial-peptide research and drug-development topic, not a peptide consumers take. Its scientific footprint sits in the broader field of cationic antimicrobial peptides (alongside LL-37, defensins, magainins, and others) but with the distinctive feature that its parent protein lactoferrin is a major component of human milk, mucosal secretions, and neutrophil granules — placing lactoferricin within a well-established system of host innate antimicrobial defense rather than positioning it as a novel synthetic antimicrobial. The 1992 Bellamy et al. discovery and 1998 Hwang NMR structure established the structural and functional basis for its broad-spectrum antimicrobial activity through cationic amphipathic membrane disruption. Subsequent work has documented activity against Gram-positive bacteria (including methicillin-resistant Staphylococcus aureus), Gram-negative bacteria (Escherichia coli, Pseudomonas aeruginosa, Salmonella), fungi (Candida albicans, Cryptococcus, Aspergillus), enveloped viruses (herpes simplex virus 1 and 2), and parasites. The apoptosis-inducing activity in tumor cell lines (Yoo 1997 Biochem Biophys Res Commun; Eliassen 2002 Anticancer Res; Mader 2005 Mol Cancer Ther) operates through mitochondrial-pathway permeabilization and has driven a smaller anticancer-development thread. Drug development has focused on derivative peptides: the 11-residue hLF1-11 (residues 1-11 of human lactoferrin) was taken into early trials by AM-Pharma for invasive fungal infections in hematopoietic stem-cell transplant recipients, though the program is effectively dormant — one completed single-dose study in 8 subjects, three further trials withdrawn without enrolling anyone, and no registry activity since, and bovine lactoferricin (Lfcin-B) and its synthetic derivatives have been explored for topical antimicrobial, food-preservation, and anti-biofilm applications. As of 2026, no lactoferricin-based product has reached broad regulatory approval, although bovine lactoferrin itself (the parent protein, not the lactoferricin fragment) is widely sold as a food supplement and is generally regarded as safe (GRAS) by the FDA. The honest framing is that lactoferricin is a well-characterized antimicrobial peptide with extensive preclinical literature, several active drug-discovery threads, and a role as a model system for understanding host-defense peptide pharmacology — but its translational chapter is incomplete.

History & Discovery

Lactoferricin was discovered in 1992 by W. Bellamy, M. Takase, K. Yamauchi, H. Wakabayashi, K. Kawase and M. Tomita at the Nutritional Science Laboratory of Morinaga Milk Industry Co. Ltd. in Zama City, Kanagawa, Japan. The team had been characterizing the antimicrobial activity of bovine lactoferrin — already recognized as a contributor to the protective antimicrobial environment of milk and mucosal secretions — and noticed that pepsin digestion of lactoferrin actually increased rather than decreased its antibacterial potency. They followed the activity through proteolytic processing and identified a 25-amino-acid peptide corresponding to residues 17-41 of bovine lactoferrin as the bactericidal core, reporting 'the existence of a previously unknown antimicrobial domain near the N-terminus of lactoferrin' in the May 1992 Biochim Biophys Acta paper and introducing the name 'lactoferricin B' in their December 1992 J Appl Bacteriol paper on its antibacterial spectrum. Companion papers in 1992-1993 from the same group characterized the antibacterial spectrum (broad against Gram-positive and Gram-negative bacteria, with synergistic effects in combination with parent lactoferrin) and the activity against Candida albicans (1993 Med Microbiol Immunol). The structural biology was completed by Hwang, Zhou, Shan, Arrowsmith, and Vogel at the University of Calgary in 1998, who reported the NMR solution structure of bovine lactoferricin in Biochemistry. The structure confirmed the amphipathic architecture stabilized by an intramolecular Cys19-Cys36 disulfide bond, with one face presenting the cationic arginine/lysine surface and the other face presenting the hydrophobic tryptophan-and-aliphatic surface — the structural signature of cationic amphipathic antimicrobial peptides. This structure provided the mechanistic basis for the cationic-amphipathic-peptide pore-forming activity that defines the class. The antiviral thread developed in the early 2000s. It is commonly anchored to van der Strate and colleagues' 2001 Antiviral Research paper, but that paper is a review of lactoferrin rather than lactoferricin and does not address the peptide; the appropriate reference for lactoferricin specifically is Jenssen's 2005 Cell Mol Life Sci review, which states that both lactoferrin and lactoferricin effectively block entry of herpes simplex virus into the host cell. The mechanism is interference with viral attachment and entry rather than direct disruption of the viral envelope, distinguishing it from the membrane-disruption antibacterial mechanism. The anticancer thread was opened in 1997 by Yoo and colleagues, who reported that bovine lactoferricin selectively killed human leukemia cells in vitro, and was substantially developed by Mader, Salsman, Conrad, and Hoskin at Dalhousie University in their 2005 Molecular Cancer Therapeutics paper showing selective induction of apoptosis in human leukemia and carcinoma cell lines through the mitochondrial pathway, driven at least in part by reactive oxygen species generation, with cytotoxic activity localized to the FKCRRWQWRM sub-sequence. Eliassen and colleagues (Anticancer Res 2002) and Mader and colleagues again (Exp Cell Res 2007) detailed the apoptosis pathway, including sequential cell-membrane permeabilization and mitochondrial targeting. The drug-discovery program around lactoferricin-derived peptides has been pursued by multiple groups across the past two decades. The most advanced clinical candidate is hLF1-11, an 11-residue fragment corresponding to residues 1-11 of human lactoferrin, developed by AM-Pharma in the Netherlands for prevention and treatment of invasive fungal infections (particularly Candida) in hematopoietic stem-cell transplant recipients — though the programme amounts to one completed single-dose study in 8 subjects and three trials withdrawn at zero enrolment. The 2016 Morici et al. paper characterized hLF1-11 inhibition of Candida biofilm formation. Other synthetic Lfcin derivatives have been explored for topical antimicrobial applications, anti-biofilm coatings on medical devices, food preservation (reviewed in the 2024 Wu et al. lactoferricin food preservation review), and combination therapy with conventional antibiotics. As of 2026, no lactoferricin-based product has reached broad regulatory approval, although bovine lactoferrin (the parent protein) remains widely available as a food supplement and is GRAS-recognized.

How It Works

Lactoferricin is the active antimicrobial fragment hidden inside lactoferrin, a protein abundant in milk and your body's mucosal secretions. When lactoferrin gets partially digested (by pepsin in your stomach, or in the lab), it releases this small peptide that punches holes in bacterial membranes and kills them. It works because lactoferricin is positively charged and partially water-loving and partially oil-loving — exactly the structure needed to grab onto the negatively-charged outer surface of bacteria and then slip into their lipid membrane and disrupt it. The same mechanism works on fungi like Candida, on enveloped viruses like herpes simplex, and even — at higher concentrations — on tumor cells through related membrane-disrupting effects. Researchers have been working on lactoferricin-derived drugs for decades, with one candidate (hLF1-11) taken into early trials for fungal infections in transplant patients, but that programme stalled after a single 8-subject study and no lactoferricin-based drug has reached approval.

Lactoferricin is generated by N-terminal proteolytic cleavage of lactoferrin, an 80-kDa iron-binding glycoprotein of the transferrin family that is abundant in mammalian milk (especially colostrum), saliva, tears, seminal fluid, bile, pancreatic secretions, and the secondary (specific) granules of neutrophils. Lactoferrin itself binds two ferric iron atoms with high affinity and contributes to nutritional, antimicrobial, and immunomodulatory functions in mucosal compartments and at sites of inflammation. The lactoferricin fragment is released by pepsin or related proteolytic activity and corresponds to bovine lactoferrin residues 17-41 (Lfcin-B, a 25-amino-acid peptide stabilized by an intramolecular disulfide bond between Cys19 and Cys36) and to human lactoferrin residues 1-47 (Lfcin-H, a longer 47-residue form with similar architecture). Bellamy and colleagues identified the bactericidal activity of pepsin-digested bovine lactoferrin as residing in this fragment in their foundational 1992 Biochim Biophys Acta paper. Structurally, lactoferricin is a cationic amphipathic peptide. Lfcin-B has a net positive charge of approximately +8 at physiological pH (the high content of arginine and lysine), a characteristic cluster of tryptophan residues at the N-terminus that contribute to membrane partitioning, and an amphipathic conformation in solution stabilized by the intramolecular disulfide. The 1998 Hwang, Zhou, Shan, Arrowsmith, and Vogel NMR structure of Lfcin-B in solution confirmed the amphipathic beta-sheet-like architecture in which one face of the peptide presents the cationic surface and the other presents the hydrophobic tryptophan-and-aliphatic surface. This architecture is the structural signature of pore-forming antimicrobial peptides shared with magainins, cecropins, and LL-37. A caveat that deserves to sit alongside every potency figure: lactoferricin's activity is highly sensitive to the physiological conditions it would actually encounter. Jones and colleagues (1994) found that activity was completely inhibited by the addition of 5% whole cow's milk and was reduced by increasing concentrations of mucin, concluding that this sensitivity to changes in physical variables raises doubts about its role in vivo. Bellamy's own spectrum paper reported that antibacterial effectiveness was reduced in the presence of sodium, potassium, magnesium or calcium ions. Much of the in vitro potency literature was generated in low-ionic-strength buffers that no mucosal surface resembles. Antimicrobial mechanism follows the canonical AMP pattern. The cationic surface binds the negatively charged lipopolysaccharide of Gram-negative outer membrane or the teichoic-acid- and phosphate-rich Gram-positive cell wall. The peptide then translocates or partially inserts into the lipid bilayer, with the hydrophobic face engaging acyl chains and the cationic face perturbing the headgroup region. At sufficient surface concentration the peptide forms transient pores that dissipate the bacterial transmembrane electrochemical gradient, causing depolarization, leak of small molecules, and ultimately cell lysis. Sub-lytic concentrations can have additional effects through translocation across the membrane and engagement of intracellular targets including nucleic acid binding, modulation of bacterial gene expression, and — as identified in the 2026 Ramamourthy et al. work in Int J Mol Sci — direct binding to bacterial acyl carrier protein (specifically helix II of the ACP), providing a named intracellular target that had previously been described only in general terms. The activity spectrum is broad but not universal, and the concentrations matter. Bellamy's founding work reported bactericidal activity between roughly 0.3 and 3.0 micromolar, with the 1992 spectrum paper giving minimum inhibitory concentrations of 0.3 to 150 micrograms/ml across species and the Candida work reporting 18 to 150 micrograms/ml. Several organisms are frankly resistant: Pseudomonas fluorescens, Enterococcus faecalis and Bifidobacterium bifidum in Bellamy's panel, and Proteus species, Pseudomonas cepacia and Serratia species in Jones's 1994 panel — note that the two papers disagree about Proteus, which Bellamy lists as susceptible and Jones as resistant. A 2026 susceptibility study of 30 clinical Acinetobacter baumannii isolates found lactoferricin largely inactive while LL-37 retained the lowest and most consistent MICs, a useful corrective to unqualified 'broad-spectrum' framing. Within that qualified spectrum the activity covers Gram-positive bacteria including Staphylococcus aureus (including MRSA strains), Gram-negative bacteria including Escherichia coli, Pseudomonas aeruginosa, and Salmonella, fungi including Candida albicans (Bellamy 1993 Med Microbiol Immunol), and enveloped viruses including herpes simplex virus 1 and 2, where both lactoferrin and lactoferricin block viral entry into the host cell rather than disrupting the virion envelope (Jenssen 2005 Cell Mol Life Sci). Structure-activity work by Pei and colleagues (2026 Front Cell Infect Microbiol) used circular dichroism and AlphaFold3 modeling to compare full-length Lfcin-B with progressively truncated variants (Lfcin B15, B9, B6) against a panel of multidrug-resistant bacterial strains, confirming that the intact 25-residue sequence together with the intramolecular Cys19-Cys36 disulfide is required for the peptide's superior broad-spectrum activity — truncation reduced potency in a length-dependent manner and destabilized the amphipathic scaffold in ionic-strength- and hydrophobic-environment-sensitive ways. Anticancer activity in tumor cell lines was first reported by Yoo and colleagues in 1997 (Biochem Biophys Res Commun), who already implicated reactive oxygen species, and was characterized in detail by Mader, Salsman, Conrad, and Hoskin at Dalhousie University (2005 Molecular Cancer Therapeutics). Lactoferricin selectively kills several human leukemia and carcinoma cell lines through a mitochondrial-pathway apoptotic mechanism: the peptide disrupts the mitochondrial outer membrane, releases cytochrome c, activates caspases, and produces apoptotic cell death. Selectivity for tumor cells over normal cells is partial. It is widely attributed to the higher proportion of negatively charged phosphatidylserine on tumor cell membranes, which is a reasonable class-level hypothesis for cationic peptides, but it is worth noting that the phosphatidylserine exposure reported in Mader 2005 was an Annexin V readout of apoptosis rather than a demonstration of the selectivity mechanism, and that paper attributed the killing itself to reactive oxygen species generation. Cidem and colleagues (2026 Int J Mol Sci) consolidated the modern cancer-translation framework for lactoferrin-derived peptides — surveying lactoferricin, lactoferrampin, LF1-11, and engineered variants incorporating non-natural amino acids, cyclization, and chemotherapeutic conjugates with respect to structure-activity relationships governing malignant-cell selectivity, intracellular trafficking, apoptotic pathways, and immune engagement alongside the persistent translational challenges of peptide stability and delivery. The family vocabulary is worth knowing, because the literature uses it constantly: the best-characterized lactoferrin-derived peptides are lactoferricin (LFcin), lactoferrampin (LFampin) and LF1-11, and engineered chimeras combining them are common. Within lactoferricin itself the core cationic motif is RRWQWR, and the minimal cytotoxic sequence identified in Mader's cancer work is FKCRRWQWRM. A further nuance the page should not gloss: the bovine and human forms are not interchangeable. Bovine lactoferricin shows broad-spectrum anticancer activity while the corresponding human-derived peptide is considerably less active, and the short peptides hLF11 and bLF10 were not cytotoxic to cancer cells at all — so hLF1-11, the lead clinical derivative, does not inherit the anticancer story that bovine Lfcin generated. Drug development has focused on derivative peptides. Most prominent is hLF1-11, an 11-residue fragment of human lactoferricin (residues 1-11 of human lactoferrin) developed by AM-Pharma in the Netherlands for prevention and treatment of invasive fungal infections (notably Candida) in hematopoietic stem-cell transplant recipients — the candidate has reached early clinical development. The 2016 Morici et al. paper characterized hLF1-11 inhibition of Candida albicans biofilm formation. Intorasoot and colleagues (2026 Antibiotics) extended the antimycobacterial characterization of the all-D form of hLF1-11 against Mycobacterium smegmatis using proteomics and imaging analysis, showing that peptide accumulation over time disrupts carbon metabolism, acetyl-CoA-dependent lipid biosynthesis, oxidative-stress defense, translational machinery, and energy production — a mechanism-level portrait of hLF1-11 activity against a mycobacterial target species relevant to tuberculosis drug discovery. Beyond hLF1-11, multiple synthetic Lfcin derivatives (including cyclized, fluorinated, and shortened analogs) have been characterized as research tools for antimicrobial structure-activity studies. None has reached broad regulatory approval as of 2026.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Lactoferricin:

• 01Whether hLF1-11 or other lactoferricin-derived peptides will reach broad regulatory approval for any antimicrobial or anticancer indication — early clinical-stage development has not yet translated into approved products.
• 02Whether the broader cationic antimicrobial peptide class can overcome the manufacturing cost, peptide stability, and emerging-resistance challenges that have limited AMP drug development across multiple peptides.
• 03The clinical relevance of lactoferricin's anticancer apoptosis-inducing activity — preclinical data are reasonably robust but human translation has not been demonstrated.
• 04Whether oral lactoferrin supplementation generates physiologically meaningful endogenous lactoferricin in the human gut, and whether this contributes to the documented immune and gastrointestinal benefits of lactoferrin supplementation.
• 05The pharmacokinetics and tissue distribution of lactoferricin-derived peptides delivered systemically, and whether stabilized analogs (cyclized, fluorinated, lipidized) can achieve adequate exposure for systemic infections.
• 06Whether lactoferricin-derived peptides have a defensible niche in antimicrobial-resistant infection management given the emergence of polymyxin- and other AMP-resistant pathogens.

Forms & Administration

Native lactoferricin is not formulated or approved as a stand-alone clinical therapeutic, but it is not absent from commerce either: a pepsin hydrolysate of lactoferrin containing lactoferricin is used as an ingredient in some infant formula, so the peptide reaches consumers as a component of a hydrolysate rather than as a defined product. Research applications use synthetic Lfcin-B and Lfcin-H for in vitro antimicrobial, antiviral, and anticancer assays, ex vivo biofilm and cell-culture pharmacology, and topical/parenteral administration in animal models. The most advanced derivative is hLF1-11 (AM-Pharma) for invasive fungal infections in hematopoietic stem-cell transplant recipients, administered intravenously — though the clinical programme comprises one completed single-dose study in 8 subjects and three withdrawn trials. Bovine lactoferrin (the parent protein) is commercially available as a food supplement (capsules, powders) and is included in some infant formulas in non-US markets. Whether oral lactoferrin supplementation generates physiologically meaningful endogenous lactoferricin in the gut depends on individual pepsin activity and other factors. Compounded lactoferricin from peptide-marketplace channels has no validated clinical use.

Common Questions

Who Lactoferricin Is NOT For

Drug & Supplement Interactions

Lactoferricin has no validated human drug-interaction profile because it is not approved as a stand-alone therapeutic. Theoretical interactions follow from its known biology. The antimicrobial activity could in principle interact with concomitant antibiotic, antifungal, or antiviral therapy — synergy with conventional antibiotics has been characterized in vitro for several Lfcin-B / antibiotic combinations. Interactions with iron supplementation or chelating agents are sometimes proposed by analogy with the parent protein, but this reasoning does not transfer: the lactoferricin domain sits in a region of lactoferrin distinct from its iron-binding sites and does not inherit that activity. Cationic peptide interactions with negatively-charged drug formulations (e.g., heparin, certain biologic drugs) are theoretically possible. None of these interactions has been characterized in controlled human studies for the lactoferricin fragment specifically.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions